<DOC>
	<DOCNO>NCT01950689</DOCNO>
	<brief_summary>The purpose study see whether add Nimorazole standard radiotherapy benefit patient locally advanced head neck squamous cell carcinoma .</brief_summary>
	<brief_title>NIMRAD ( A Randomised Placebo-controlled Trial Synchronous NIMorazole Versus RADiotherapy Alone Patients With Locally Advanced Head Neck Squamous Cell Carcinoma Not Suitable Synchronous Chemotherapy Cetuximab )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Nimorazole</mesh_term>
	<criteria>Histologically confirm head neck squamous cell carcinoma ; primary subsites EXCEPT nasal cavity , oral cavity , nasopharynx paranasal sinus ( i.e . oropharynx , hypopharynx , larynx allow ) Stage T3/T4 N0 ; node +ve case include T1 node +ve ; T2N0 base tongue/hypopharynx Patients suitable definitive radiotherapy . Block dissection may perform preRT N2/N3 disease WHO status 02 Patient fit able undergo RT nimorazole expect complete treatment Absence another disease previous malignancy likely interfere treatment assessment response No evidence distant metastasis ( M0 ) Unable tolerate/unlikely benefit platinum chemotherapy monoclonal antibody therapy Women must postmenopausal ( menstrual period minimum 1 year ) negative serum pregnancy test entry study ( even surgically sterilise ) use adequate contraception method . This must continue 1 week completion nimorazole , unless child bear potential terminate surgery/radical radiotherapy Men must willing use adequate method contraception chemotherapy 1 week nimorazole Greater 18 year age ; upper age limit Available follow within United Kingdom Adequate renal liver function absolute neutrophil count &gt; =1.5 x 109/L , creatinine &lt; =2x ULN , platelets &gt; 100x109/L , bilirubin &lt; =2 x ULN , AST &lt; 3 x ULN The capacity understand patient information sheet ability provide write informed consent Willingness ability comply schedule visit , treatment plan , laboratory test study procedure Patients T1N0 tumour within nasopharynx , nasal cavity sinus , oral cavity ; T2No larynx tonsil ; unknown primary cancer . Any prior chemotherapy last 6 month RT within plan radiation field Presence life threaten illness unstable angina severe chronic obstructive pulmonary disease Mental disability patient otherwise unable give inform consent and/or complete patient questionnaire Hb &lt; 100 g/l ( patient anaemia may transfuse bring Hb level &gt; 100 g/l within 1 week treatment start . Please repeat Hb follow transfusion confirm eligible ) Peripheral neurophathy assess clinically ( CTCAE &gt; =2 ) Use investigational drug within 30 day prior screen Severe and/or uncontrolled medical disease Any malabsorption syndrome ( i.e . partial gastrectomy , small bowel resection , Crohn 's disease ulcerative colitis ) Use Lithium Phenobarbitone study Patients breastfeed pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>